Taking the bold steps needed to make the small ones possible.

Oxyrane develops BBB-crossing enzyme replacement therapies (ERT) for CNS manifestations of lysosomal storage diseases (LSDs). By applying its proprietary robust and scalable glyco-engineering yeast platform and proprietary BBB-crossing tags, Oxyrane produces human lysosomal enzymes containing appropriate sugar structures, which enable superior product uptake and localization, resulting in greater efficacy at lower product doses.

  • CEO Evert Kueppers
  • Industry Biotech